310 related articles for article (PubMed ID: 32068087)
1. Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy.
Gupta B; Sadaria D; Warrier VU; Kirtonia A; Kant R; Awasthi A; Baligar P; Pal JK; Yuba E; Sethi G; Garg M; Gupta RK
Semin Cancer Biol; 2022 May; 80():87-106. PubMed ID: 32068087
[TBL] [Abstract][Full Text] [Related]
2. Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy.
Makandar AI; Jain M; Yuba E; Sethi G; Gupta RK
Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560459
[TBL] [Abstract][Full Text] [Related]
3. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
4. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
[TBL] [Abstract][Full Text] [Related]
5. Targeting C-type lectin receptors with multivalent carbohydrate ligands.
Lepenies B; Lee J; Sonkaria S
Adv Drug Deliv Rev; 2013 Aug; 65(9):1271-81. PubMed ID: 23727341
[TBL] [Abstract][Full Text] [Related]
6. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
7. From structure to function - Ligand recognition by myeloid C-type lectin receptors.
Fischer S; Stegmann F; Gnanapragassam VS; Lepenies B
Comput Struct Biotechnol J; 2022; 20():5790-5812. PubMed ID: 36382179
[TBL] [Abstract][Full Text] [Related]
8. C-type lectins on dendritic cells: key modulators for the induction of immune responses.
van Kooyk Y
Biochem Soc Trans; 2008 Dec; 36(Pt 6):1478-81. PubMed ID: 19021579
[TBL] [Abstract][Full Text] [Related]
9. Frontal affinity chromatography analysis of constructs of DC-SIGN, DC-SIGNR and LSECtin extend evidence for affinity to agalactosylated N-glycans.
Yabe R; Tateno H; Hirabayashi J
FEBS J; 2010 Oct; 277(19):4010-26. PubMed ID: 20840590
[TBL] [Abstract][Full Text] [Related]
10. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
11. Biological evaluation of multivalent lewis X-MGL-1 interactions.
Eriksson M; Serna S; Maglinao M; Schlegel MK; Seeberger PH; Reichardt NC; Lepenies B
Chembiochem; 2014 Apr; 15(6):844-51. PubMed ID: 24616167
[TBL] [Abstract][Full Text] [Related]
12. Glycan-Gold Nanoparticles as Multifunctional Probes for Multivalent Lectin-Carbohydrate Binding: Implications for Blocking Virus Infection and Nanoparticle Assembly.
Budhadev D; Poole E; Nehlmeier I; Liu Y; Hooper J; Kalverda E; Akshath US; Hondow N; Turnbull WB; Pöhlmann S; Guo Y; Zhou D
J Am Chem Soc; 2020 Oct; 142(42):18022-18034. PubMed ID: 32935985
[TBL] [Abstract][Full Text] [Related]
13. Using the glycan toolbox for pathogenic interventions and glycan immunotherapy.
Li RE; van Vliet SJ; van Kooyk Y
Curr Opin Biotechnol; 2018 Jun; 51():24-31. PubMed ID: 29175707
[TBL] [Abstract][Full Text] [Related]
14. Melanoma tumour-derived glycans hijack dendritic cell subsets through C-type lectin receptor binding.
Niveau C; Sosa Cuevas E; Roubinet B; Pezet M; Thépaut M; Mouret S; Charles J; Fieschi F; Landemarre L; Chaperot L; Saas P; Aspord C
Immunology; 2024 Feb; 171(2):286-311. PubMed ID: 37991344
[TBL] [Abstract][Full Text] [Related]
15. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.
Duinkerken S; Horrevorts SK; Kalay H; Ambrosini M; Rutte L; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
Theranostics; 2019; 9(20):5797-5809. PubMed ID: 31534520
[TBL] [Abstract][Full Text] [Related]
16. Glycans from avian influenza virus are recognized by chicken dendritic cells and are targets for the humoral immune response in chicken.
de Geus ED; Tefsen B; van Haarlem DA; van Eden W; van Die I; Vervelde L
Mol Immunol; 2013 Dec; 56(4):452-62. PubMed ID: 23911401
[TBL] [Abstract][Full Text] [Related]
17. TETRALEC, Artificial Tetrameric Lectins: A Tool to Screen Ligand and Pathogen Interactions.
Achilli S; Monteiro JT; Serna S; Mayer-Lambertz S; Thépaut M; Le Roy A; Ebel C; Reichardt NC; Lepenies B; Fieschi F; Vivès C
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722514
[TBL] [Abstract][Full Text] [Related]
18. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells.
Aarnoudse CA; Bax M; Sánchez-Hernández M; García-Vallejo JJ; van Kooyk Y
Int J Cancer; 2008 Feb; 122(4):839-46. PubMed ID: 17957800
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of human dendritic cell inhibitory receptor C-type lectin domain reveals the binding mode with N-glycan.
Nagae M; Ikeda A; Hanashima S; Kojima T; Matsumoto N; Yamamoto K; Yamaguchi Y
FEBS Lett; 2016 Apr; 590(8):1280-8. PubMed ID: 27015765
[TBL] [Abstract][Full Text] [Related]
20. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells.
Nonaka M; Ma BY; Murai R; Nakamura N; Baba M; Kawasaki N; Hodohara K; Asano S; Kawasaki T
J Immunol; 2008 Mar; 180(5):3347-56. PubMed ID: 18292560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
